Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 3822971 in Advanced or Metastatic Solid Cancers
NCT07744152Phase 1Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Primary completion
- Jan 2030
- Countries
- 5
01
Overview
Phase 1, open-label, single-arm trial of BI 3822971 in solid tumor, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and 5 more, sponsored by Boehringer Ingelheim. Primary endpoints: Occurrence of treatment-emergent adverse events at 36 months and Occurrence of dose limiting toxicities at 36 months. Started Sep 2026; status: recruiting.
02
Drugs
BI 3822971
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)triple-negative breast cancer (TNBC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07744152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07744152.